Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-01, Stock:ABBV, The news for the past five days is as follows:
2019-04-24: NEWS1: Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?.NEWS2: Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?.NEWS3: Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?.NEWS4: Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?.NEWS5: Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?.NEWS6: Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?.NEWS7: Pre-Market Earnings Report for April 25, 2019 :  CMCSA, MMM, ABBV, MO, UPS, BMY, RTN, ITW, MMC, WM, AEP, BAX.NEWS8: Pre-Market Earnings Report for April 25, 2019 :  CMCSA, MMM, ABBV, MO, UPS, BMY, RTN, ITW, MMC, WM, AEP, BAX.NEWS9: AbbVie Expected to Earn $2.06 a share.NEWS10: 5 Turnaround Earnings Charts You Must See.NEWS11: 5 Turnaround Earnings Charts You Must See.NEWS12: Why Earnings Season Could Be Great for AbbVie (ABBV).NEWS13: Why Earnings Season Could Be Great for AbbVie (ABBV).NEWS14: Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales.NEWS15: Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales.NEWS16: AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect.NEWS17: 5 Turnaround Earnings Charts You Must See.NEWS18: Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales.NEWS19: Why Earnings Season Could Be Great for AbbVie (ABBV).NEWS20: The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova.
2019-04-25: NEWS1: AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript.NEWS2: AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript.NEWS3: AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript.NEWS4: Noteworthy Thursday Option Activity: INTC, RTN, ABBV.NEWS5: Noteworthy Thursday Option Activity: INTC, RTN, ABBV.NEWS6: These Pharmas Beat First-Quarter Forecasts; But Biosimilars Rankled One.NEWS7: AbbVie Climbs Earnings Beat, Guidance Boost.NEWS8: What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings.NEWS9: What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings.NEWS10: What You Need to Know About AbbVie&apos;s Surprisingly Strong Q1 Earnings.NEWS11: AbbVie Slips in Spite of Earnings Beat, Guidance Boost.NEWS12: AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View.NEWS13: AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View.NEWS14: Here&apos;s Why The Bacteria In Your Gut Could Be A Blockbuster Opportunity.NEWS15: AbbVie raises profit forecast, but Humira concerns weigh on shares.NEWS16: AbbVie raises profit forecast, but Humira concerns weigh on shares.NEWS17: AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up.NEWS18: AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up.NEWS19: AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View.NEWS20: AbbVie Is Losing Its Humira Safety Blanket.NEWS21: AbbVie says Humira rivals from Biogen, Amgen most aggressive so far.NEWS22: Health Care Sector Update for 04/25/2019: ABBV, BAX, BMY, JNJ, PFE, MRK, ABT, AMGN.NEWS23: Health Care Sector Update for 04/25/2019: ABBV, BAX, BMY, JNJ, PFE, MRK, ABT, AMGN.NEWS24: AbbVie, Bristol Earnings Top First-Quarter Estimates.NEWS25: AbbVie beats estimates as Humira sales fall less than feared.NEWS26: AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up.NEWS27: AbbVie beats estimates as Humira sales fall less than feared.NEWS28: AbbVie raises forecasts despite pressure on Humira.NEWS29: AbbVie Climbs on Earnings Beat, Guidance Boost.NEWS30: AbbVie stock up 2% after earnings beat and raised outlook.NEWS31: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings.NEWS32: AbbVie: 1Q Earnings Snapshot.NEWS33: AbbVie beats estimates as Humira sales fall less than feared.NEWS34: AbbVie Reports First-Quarter 2019 Financial Results.NEWS35: AbbVie Earnings, Revenue Beat in Q1.
2019-04-26: NEWS1: Edited Transcript of ABBV earnings conference call or presentation 25-Apr-19 1:00pm GMT.NEWS2: 2 Large Drug Manufacturers Release 1st-Quarter Results.NEWS3: Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer.NEWS4: 3 Big Stock Charts for Friday: AbbVie, ConocoPhillips and MGM Resorts.NEWS5: 3 Big Stock Charts for Friday: AbbVie, ConocoPhillips and MGM Resorts.NEWS6: 3 Big Stock Charts for Friday: AbbVie, ConocoPhillips and MGM Resorts.
2019-04-29: NEWS1: Better Big Pharma Stock: AbbVie vs. AstraZeneca.NEWS2: Better Big Pharma Stock: AbbVie vs. AstraZeneca.NEWS3: Better Big Pharma Stock: AbbVie vs. AstraZeneca.NEWS4: AbbVie Raises EPS Guidance for Fiscal 2019.NEWS5: AbbVie Reiterates Revenue Guidance for Fiscal 2019.NEWS6: What Analysts Are Recommending for AbbVie after Q1 Results.NEWS7: 3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV).NEWS8: 3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV).NEWS9: AbbVie (ABBV) Upgraded to Buy: Here's Why.NEWS10: AbbVie (ABBV) Upgraded to Buy: Here's Why.NEWS11: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS12: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS13: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS14: A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug.NEWS15: AbbVie (ABBV) Upgraded to Buy: Here's Why.NEWS16: 3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV).NEWS17: Here are the biggest analyst calls of the day: Target, Disney, CVS, American Airlines, & more.NEWS18: Here are the biggest analyst calls of the day: Target, Disney, CVS, American Airlines, & more.
2019-04-30: NEWS1: Financial Exchange Stock Talk: Dividend Sensei On AbbVie.NEWS2: Financial Exchange Stock Talk: Dividend Sensei On AbbVie.NEWS3: Top Stock Reports for Facebook, Comcast & AbbVie.NEWS4: Neurocrine Biosciences Has Robust Late-Stage Pipeline.NEWS5: European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis.NEWS6: AbbVie’s Guidance for Second Quarter of Fiscal 2019.NEWS7: AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting.

Answer: Decrease